Search Results
Your search for it matches 15885 pages
Showing 101 - 150Perioperative Immunotherapy Regimen Improves Outcomes in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
A perioperative regimen of the antibody-drug conjugate enfortumab vedotin-ejfv plus the PD-1 inhibitor pembrolizumab significantly improved outcomes vs radical cystectomy alone in patients with muscle-invasive bladder cancer who were ineligible for or declined cisplatin-based chemotherapy. Results...
President Biden Completes Radiation Therapy Course
President Joe Biden has completed his course of radiation therapy for prostate cancer, which he recently marked by ringing the ceremonial bell alongside his radiation oncology care team. According to a report from People, President Biden’s daughter Ashley Biden shared the moment on her Instagram...
PD-L1 Plus CTLA-4 Inhibition for Renal Cell Carcinoma Following Resection: RAMPART
Combination immunotherapy significantly improved disease-free survival after surgery in patients with primary renal cell carcinoma (RCC), according to results from the phase III RAMPART trial. These findings were presented at the European Society for Medical Oncology (ESMO) Congress 2025 by James...
How the Proliferation of Fraudulent Scientific Papers Is Threatening the Integrity of Cancer Research
There is a perception among many scientists that scientific fraud is a rare occurrence, resulting from the actions of a few isolated bad actors. However, an extensive investigation by Reese A.K. Richardson, PhD, postdoctoral fellow at the Center for Science of Science and Innovation, Kellogg School ...
Defying the Odds
In early 2023, I began experiencing serious symptoms that were not easily explained away, including deep vein thrombosis in my left leg, extreme weight loss, bruising, wheezing, and shortness of breath so severe that it was difficult to walk my dog more than a few feet without gasping for air. For...
Biomarker-Driven Apalutamide Therapy for Patients With Recurrent Prostate Cancer
Use of PAM50 subtyping allowed clinicians to determine which patients with recurrent prostate cancer were most likely to benefit from the addition of apalutamide hormonal therapy to salvage radiotherapy, according to findings from the phase II BALANCE trial (NRG GU006). These results were presented ...
Medicine Is in the Genes of Neelima Denduluri, MD, FASCO, a Third-Generation Clinician
Growing up in Draksharamam, a small village in India, Neelima Denduluri, MD, FASCO, was attracted to the field of medicine after witnessing her grandfather, a general practitioner in the village, care for patients so poor he often provided medical services at no cost. Although Dr. Denduluri’s...
How a $2 Billion Gift to the Knight Cancer Institute May Accelerate Cancer Advances and Streamline Care for Patients
On August 14, 2025, Oregon Health & Science University (OHSU) announced that Phil Knight, a cofounder of Nike, and his wife, Penny, donated $2 billion to the OHSU Knight Cancer Institute. The record-setting gift is the largest single donation ever made to a U.S. university, college, or academic ...
AGA Issues New Guideline Urging Risk-Based Surveillance in Barrett’s Esophagus
The American Gastroenterological Association (AGA) has released an updated clinical practice guideline on surveillance of Barrett’s esophagus, the only known precursor to esophageal adenocarcinoma. The new guideline, which was published in Gastroenterology, emphasizes risk-based, individualized...
New Guideline Reflects the Latest Evidence in Support of Postmastectomy Radiation Therapy for Patients With Breast Cancer
A joint task force composed of experts from the American Society of Radiation Oncology (ASTRO), ASCO, and the Society of Surgical Oncology (SSO) has released new guidance for postmastectomy radiation therapy (PMRT) for patients with breast cancer.1 This guideline—which is intended to replace the...
How Embedding an Algorithm-Based Referral System Into Electronic Health Records Is Increasing Access to Palliative Care
Despite numerous studies showing the benefits of integrating palliative care in both the early- and advanced-stage cancer settings,1 palliative care remains underutilized for most patients with cancer. A recent study by the American Cancer Society found that only 10% of Medicare beneficiaries with...
ESMO Publishes Guidance on Large Language Model Use for Oncology Practice
The European Society for Medical Oncology (ESMO) has released its first set of recommendations for the use of artificial intelligence (AI) large language models in oncology practice, called the ESMO Guidance on the Use of Large Language Models in Clinical Practice (ELCAP). The guidance was...
Reversible TKI in HER2-Mutant NSCLC
The oral targeted therapy sevabertinib led to tumor reduction and manageable side effects in patients with HER2-mutant non–small cell lung cancer (NSCLC), according to data from the phase I/II SOHO-01 clinical trial. Over 70% of the patients studied saw their tumors shrink or disappear. The results ...
Adjuvant Pembrolizumab in Merkel Cell Carcinoma
A new clinical trial from the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) presented at the European Society for Medical Oncology (ESMO) 2025 Congress found that adjuvant therapy with the PD-1 inhibitor pembrolizumab appeared to reduce the risk of distant metastases for an aggressive form of skin...
Final FLAURA2 Analysis Confirms First-Line Benefit of Osimertinib/Chemotherapy in EGFR-Positive NSCLC
The combination of osimertinib plus chemotherapy led to a median overall survival of 47.5 months compared with 37.6 months with osimertinib monotherapy in patients with EGFR-mutated advanced non–small cell lung cancer (NSCLC) who had not received prior treatment for advanced disease, according to...
Muscle-Invasive Bladder Cancer: IMvigor011 Trial Investigates ctDNA-Guided Adjuvant PD-L1 Inhibition
Patients with muscle-invasive bladder cancer who tested positive for circulating tumor DNA (ctDNA) after cystectomy may benefit from immunotherapy with the PD-L1 inhibitor atezolizumab compared to placebo, whereas ctDNA-negative patients may potentially be spared unnecessary treatment. These...
Belzutifan Achieves Durable Responses Without Surgery in Advanced Pheochromocytoma/Paraganglioma
Belzutifan induced durable responses without surgery in patients with advanced pheochromocytoma or paraganglioma and demonstrated manageable safety in the phase II LITESPARK-015 trial, according to findings presented during the European Society for Medical Oncology (ESMO) Congress 2025 (Abstract...
Metastatic ER-Positive, HER2-Negative Breast Cancer: Novel Treatment Combination Improves Progression-Free Survival
Patients with estrogen receptor (ER)-positive, HER2-negative advanced breast cancer showed significantly improved progression-free survival when treated with an oral combination regimen that includes giredestrant, a next-generation oral selective estrogen receptor degrader (SERD) and full...
mRNA-Based COVID Vaccines May Generate Improved Responses to Immunotherapy
Patients with cancer who received mRNA-based COVID vaccines within 100 days of starting immune checkpoint therapy were twice as likely to be alive 3 years after beginning treatment, according to a recent study. These findings, which include more than 1,000 patients treated between August 2019 and...
Cutaneous T-Cell Lymphoma: Use of Durvalumab Alone or With Lenalidomide Under Study in Phase II Trial
In a randomized phase II trial, Christiane Querfeld, MD, PhD, and colleagues investigated the effects of a PD-L1–blocking strategy for targeting both the innate and adaptive immune systems in cutaneous T-cell lymphoma (CTCL). At the 2025 Society of Hematologic Oncology (SOHO) Annual Meeting,1 Dr....
Survival With Dual CTLA-4 and PD-L1/PD-1 Blockade in Advanced NSCLC
In a systematic review and reconstructed individual-patient meta-analysis reported in The Lancet Oncology, Di Federico et al found that dual CTLA-4 and PD-L1 or PD-1 blockade did not result in improved long-term survival overall vs single PD-L1 or PD-1 blockade in patients with advanced non–small...
Palliative Care Remains Underused Among Young Adults With Advanced Cancer
Although palliative care use has increased over time among young adults with advanced cancers in the United States, new research led by the American Cancer Society (ACS) found that utilization still remains very low. The report was presented at the 2025 ASCO Quality Care Symposium (Abstract 320)....
10-Year Incidence of Second Cancers in HPV-Positive Oropharyngeal Cancer
At 10 years, the cumulative incidence of radiation-induced second malignancies in patients receiving definitive radiation therapy for human papillomavirus (HPV)–associated oropharyngeal cancers was 1.74%, according to findings culled from the Cleveland Clinic Cancer Institute database. These...
Alcohol and Cancer Risk: Is a Drop Too Much?
In 2022, Congress requested a scientific review from the National Academies of Sciences, Engineering, and Medicine (NASEM) to study the associated risks of cancer and other health conditions and the use of alcohol. The concern was that the health risks associated with low-to-moderate consumption of ...
Study Confirms It’s ‘Never Too Late’ to See Survival Benefits From Quitting Smoking—Even With Late-Stage Cancer
New research published by Tohmasi et al in JNCCN—Journal of the National Comprehensive Cancer Network has found that people with cancer who quit smoking had a much lower risk of dying within 2 years compared to those who kept smoking. Researchers followed more than 13,000 individuals with cancer,...
Armando E. Giuliano, MD, To Be Honored With 2025 William L. McGuire Memorial Lecture Award at SABCS
Armando E. Giuliano, MD, will receive the William L. McGuire Memorial Lecture Award during the 2025 San Antonio Breast Cancer Symposium (SABCS). Dr. Giuliano is being recognized for his pioneering work on sentinel lymph node biopsy for patients with breast cancer, which has transformed the...
Fertility-Sparing Surgery vs Hysterectomy for Early-Stage Cervical Cancer: Comparable Survival Rates but Higher Recurrence Risk
In a nationwide study published in JCO Oncology Practice, Wolswinkel et al evaluated the long-term oncologic safety of fertility-sparing surgery (FSS) compared with hysterectomy in women with early-stage cervical cancer. The study—one of the largest of its kind—addresses a critical question for...
Creatine
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. In this installment, Yen Nien (Jason) Hou, PharmD, DiplOM, LAc, and Jyothirmai Gubili, MS, focus...
Incidence of Invasive Lobular Carcinoma Rising Faster Than Other Breast Cancers
Incidence rates for invasive lobular carcinoma have increased more drastically than all other breast cancers combined between 2012 and 2021, according to findings from the American Cancer Society’s Lobular Breast Cancer Statistics 2025 report, published in Cancer. “Although lobular breast cancer...
Financial Toxicity Tied to Increased Risk of Mortality Among Patients With Cancer
Patients with cancer who developed financial toxicity and falling credit scores faced higher mortality risks, according to findings from a study presented at the American College of Surgeons (ACS) Clinical Congress 2025 and published in the Journal of the American College of Surgeons. “Our work...
Antidepressants May Improve Surgical Outcomes in Patients With GI Cancer and Depression
New research revealed that depression can impact surgical outcomes, making it more difficult for patients to recover from surgery, thus leading to higher postoperative costs as well. In patients with gastrointestinal cancers and depression who were undergoing surgery specifically, antidepressants...
Mastectomy Linked to Worsened Sexual Health and Body Image After Surgery, Study Finds
Although mastectomy is often a necessary and life-saving treatment option for many women with breast cancer, the surgery may contribute to worse sexual health, body image, and several other physical and emotional challenges after surgery, according to a recent systematic review on the effects of...
Considerations on Cancer Drug Development
In the 1940s, the first drugs proven to cause objective responses in human cancers were developed. Mechlorethamine was discovered as a possible treatment of lymphoid cancers after autopsies on military personnel exposed to mustard gas found destruction of lymphatic tissue and bone marrow....
FANSS: Should Lung Cancer Screening Guidelines Be Expanded to Include Female Asian Nonsmokers?
The results of the multicenter Female Asian Nonsmoker Screening Study (FANSS) suggest that low-dose CT screening is feasible and has value for early lung cancer detection in the historically underserved demographic of Asian women with no history of smoking. These data from the largest United...
Improved Outcomes Reported With Second-Line Regimen of Ivonescimab Plus Chemotherapy in NSCLC
In the phase III HARMONi trial, when ivonescimab was given with carboplatin plus pemetrexed, vs the chemotherapy regimen alone, after a third-generation tyrosine kinase inhibitor, patients with EGFR-mutated non–small cell lung cancer (NSCLC) had a significant delay in disease progression.1...
Pulsed Low-Dose–Rate Chemoradiation Reduces Severe Esophagitis in Esophageal Cancer and NSCLC
Chemoradiation with a pulsed low-dose–rate technique led to lower-than-usual rates of severe esophagitis without compromising efficacy in patients with esophageal and non–small cell lung cancer (NSCLC), according to findings from a single-arm phase I study presented as a poster during the American...
Predicting Future Breast Cancer Outcomes: Efficacy of a Polygenic Risk Score
Studies show that if left untreated, between 20% and 40% of ductal carcinoma in situ (DCIS) lesions may evolve into invasive breast cancer over time. And, according to the American Cancer Society, women diagnosed with lobular carcinoma in situ (LCIS) have between a 7 and 12 times higher risk of...
Breast Volume Preservation Comparable After Five-Fraction Whole- or Partial-Breast Radiotherapy
No significant differences were observed in breast volume loss between five-fraction whole-breast and partial-breast radiation therapy in patients with breast cancer who underwent prior partial mastectomy, according to the results of a study presented in a poster during the American Society for...
Association of Survival With Treatment Recommendation and Receipt in Older Patients With Early-Stage Cervical Cancer
In a retrospective cohort study reported in JAMA Network Open, Suk et al identified the association of survival with receipt of recommended treatment and nonreceipt of nonrecommended treatment among patients aged ≥ 65 years with newly diagnosed early-stage cervical cancer. Study Details The study...
Use of Obecabtagene Autoleucel CAR T-Cell Therapy for B-Cell Acute Lymphocytic Leukemia
Treatment with obecabtagene autoleucel was the focus of the phase Ib/II multicenter FELIX study of more than 100 adults with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL).1 The initial report in 2024 revealed a rate of complete remission or complete remission with incomplete...
Medicare Telehealth Flexibilities and CMS Operations During Government Shutdown
The U.S. government shut down on October 1 after lawmakers were unable to reach a funding agreement. The date also marked the deadline to extend the Medicare telehealth flexibilities that have been in place since the COVID-19 public health emergency (PHE). As such, telehealth flexibilities have...
In Extensive-Stage Small Cell Lung Cancer, Novel Maintenance Regimen Boosts Overall Survival
The phase Ib DeLLphi-303 trial has reported overall survival data for a novel maintenance regimen in extensive-stage small cell lung cancer following first-line chemoimmunotherapy. Patients treated with the bispecific T-cell engager tarlatamab-dlle plus a PD-L1 inhibitor had a median overall...
CT-Adapative SBRT for Recurrent Retroperitoneal Sarcomas
For patients with recurrent retroperitoneal sarcomas that cannot be treated surgically, treatment choices are limited. These tumors can grow in the abdomen adjacent to vital organs or enmeshed within the bowel. Given their radioresistant nature, they require high doses of radiation that risk...
Variation in PSA Levels in Annual Testing Among Individuals Without a Prostate Cancer Diagnosis
In a study reported in JAMA Oncology,1 Nicholas A. Pickersgill, MD, of the Department of Surgery (Urology Service) at Memorial Sloan Kettering Cancer Center, New York, and colleagues found that individuals without prostate cancer undergoing annual prostate-specific antigen (PSA) testing often...
Impact of Proton and Photon Therapies on HRQOL in Breast Cancer
Health-related quality-of-life measurements demonstrated that both proton and photon radiation therapies led to excellent and similar impacts on quality of life for patients with breast cancer undergoing comprehensive nodal irradiation, according to findings from the phase III RadComp trial that...
Intermediate-Risk Prostate Cancer: Shorter Radiation Improves Patient Experience, But Not Disease Control
For patients with intermediate-risk, localized prostate cancer, radiation therapy delivered in five sessions reduced patient-reported side effects compared to longer courses of radiation, according to results of a large, randomized phase III trial. Patients treated with stereotactic body radiation...
Oropharyngeal Cancer Quality-of-Life Outcomes: IMRT vs Proton-Beam Therapy
A new phase III clinical trial has found that intensity-modulated radiation therapy (IMRT) and proton-beam therapy resulted in similar quality-of-life outcomes and low rates of side effects for people with locally advanced oropharyngeal cancer. The TORPEdO trial, a randomized study conducted across ...
SABR May Be Comparable to Surgery for Early-Stage NSCLC
Stereotactic radiation therapy (SABR) was found to be noninferior to surgical resection in terms of overall survival for patients with early-stage non–small cell lung cancer (NSCLC), according to 10-year results from the STARS trial presented at the American Society for Radiation Oncology (ASTRO)...
NCI Issues Request for 2027 Budget
The National Cancer Institute (NCI) is requesting over $11.5 billion in federal funding for fiscal year (FY) 2027, an increase of more than $4 billion from FY25. The agency shared the request on September 27 in its FY27 Professional Judgment Budget Proposal. The proposal—also known as a “bypass...
Adjuvant Radiation Therapy Safe and Beneficial in Locally Advanced Muscle-Invasive Bladder Cancer
Adjuvant radiation therapy following radical cystectomy and chemotherapy was found to be safe and efficacious for patients with locally advanced muscle-invasive bladder cancer, according to findings from the phase III randomized BART trial presented at the American Society for Radiation Oncology...
